{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.61","value":"4.0"},{"groupId":"OG001","spread":"18.84","value":"6.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"491"},{"groupId":"OG001","value":"486"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Maximum improvement is the best post-baseline change.","dispersionType":"Standard Deviation","groups":[{"description":"On Day 1 of each 14-day cycle, participants received ramucirumab followed by other study treatment in the following sequence: Irinotecan, Folinic Acid and 5-Fluorouracil. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\nRamucirumab: 8 mg/kg administered intravenously.\n\nIrinotecan: 180 mg/m\\^2 administered intravenously.\n\nFolinic Acid: 400 mg/m\\^2 administered intravenously.\n\n5-Fluorouracil: 400 mg/m\\^2 bolus immediately followed by 2400 mg/m\\^2 continuous infusion.","id":"OG000","title":"Ramucirumab + FOLFIRI"},{"description":"On Day 1 of each 14-day cycle, participants received placebo followed by other study treatment in the following sequence: Irinotecan, Folinic Acid and 5-Fluorouracil. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\nPlacebo: Administered intravenously.\n\nIrinotecan: 180 mg/m\\^2 administered intravenously.\n\nFolinic Acid: 400 mg/m\\^2 administered intravenously.\n\n5-Fluorouracil: 400 mg/m\\^2 bolus immediately followed by 2400 mg/m\\^2 continuous infusion.","id":"OG001","title":"Placebo + FOLFIRI"}],"paramType":"MEAN","populationDescription":"All randomized participants who had EORTC QLQ-C30 assessed at baseline and post-baseline .","reportingStatus":"POSTED","timeFrame":"Baseline Up to 171 Weeks","title":"Change From Baseline in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 Global Health Status","type":"SECONDARY","unitOfMeasure":"units on a scale"}